MPP(+)-induced degeneration is potentiated by dicoumarol in cultures of the RCSN-3 dopaminergic cell line. Implications of neuromelanin in oxidative metabolism of dopamine neurotoxicity.
We have tested the idea that oxidative metabolism of dopamine may be involved in MPTP toxicity using the RCSN-3 cell line derived from the substantia nigra of an adult rat. Treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (10 microM), MPTP combined with 40 microM dicoumarol (an inhibitor of DT-diaphorase) and dicoumarol alone, did not induce toxicity in RCSN-3 cells after 72 h incubation. The lack of toxicity in MPTP-treated RCSN-3 cells may be explained by the fact that they are unable to metabolize MPTP to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinium ion (MPP+ as determined by HPLC. Incubation for 72 h with 100 microM MPP+ induced a 6.6 +/- 1.4% cell death of RCSN-3 cells compared to 3.5 +/- 0.4 observed in control cells. However, when the cells were treated with 100 microM MPP+ and 40 microM dicoumarol, cell death increased 4-fold compared to that of cells treated solely with MPP+ (27 +/- 2%; P<0.001). Under these conditions, a significant increase in DNA fragmentation (3-fold compared to MPP+ alone; P<0.01) and in calpain activation (P<0.05 compared to control) was evident. The inhibition of DT-diaphorase by dicoumarol supports the idea that oxidative metabolism of dopamine is involved in MPP+ toxicity in RCSN-3 cells.
Aguilar Hernández
R
R
Experimental Neurology and Neurosurgery, Department of Human Anatomy and Psychobiology, School of Medicine, University of Murcia, Spain.
Sánchez De Las Matas
M J
MJ
Arriagada
C
C
Barcia
C
C
Caviedes
P
P
Herrero
M T
MT
Segura-Aguilar
J
J
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000378:metabolism; D015655:1-Methyl-4-phenylpyridinium / Q000633:toxicity*; D000818:Animals; D002154:Calpain / Q000378:metabolism; D016923:Cell Death / Q000187:drug effects; D002460:Cell Line; D002851:Chromatography, High Pressure Liquid; D053938:DNA Fragmentation / Q000187:drug effects; D001728:Dicumarol / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism / Q000502:physiology*; D015259:Dopamine Agents / Q000633:toxicity*; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D008543:Melanins / Q000502:physiology*; D016660:NAD(P)H Dehydrogenase (Quinone) / Q000037:antagonists & inhibitors; D009410:Nerve Degeneration / Q000139:chemically induced* / Q000473:pathology; D010084:Oxidation-Reduction; D051381:Rats
D015259:Dopamine Agents; D004791:Enzyme Inhibitors; D008543:Melanins; C014121:neuromelanin; D001728:Dicumarol; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D016660:NAD(P)H Dehydrogenase (Quinone); D002154:Calpain; D015655:1-Methyl-4-phenylpyridinium; D004298:Dopamine